Recap: Paratek Pharmaceuticals Q2 Earnings

Shares of Paratek Pharmaceuticals PRTK rose 2.3% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 48.04% over the past year to ($0.53), which may not compare to the estimate of ($0.06).

Revenue of $9,326,000 up by 356.04% year over year, which missed the estimate of $38,030,000.

Guidance

The upcoming fiscal year's revenue expected to be between $78,000,000 and $83,000,000.

Details Of The Call

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1349521&tp_key=c438ff6805

Recent Stock Performance

Company's 52-week high was at $6.41

Company's 52-week low was at $2.50

Price action over last quarter: Up 4.50%

Company Profile

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. Omadacycline is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. Sarecycline is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.